Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy

被引:10
|
作者
DeBernardo, RL
Perkins, RB
Littell, RD
Krasner, CN
Duska, LR
机构
[1] Massachusetts Gen Hosp, Div Gynecol Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA
来源
OBSTETRICS AND GYNECOLOGY | 2005年 / 105卷 / 05期
关键词
D O I
10.1097/01.AOG.0000153026.61249.c7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To compare the efficacy of dalteparin, a low-molecular-weight heparin, to unfractionated heparin (UFH) in the prevention of deep venous thrombosis (DVT) and pulmonary embolism in patients after surgery for gynecologic malignancy. METHODS: The medical records of all patients undergoing major surgery on the Gynecologic Oncology Service at the Massachusetts General Hospital from July 2002 through April 2003 were reviewed. Patients with confirmed malignancy were included. Between July 1, 2002, and November 15, 2002, dalteparin (5,000 U subcutaneously each day) was used for postoperative prophylaxis for DVT and pulmonary embolus. After November 15, 2002, the method of prophylaxis was changed to UFH (5,000 U subcutaneously every 8 hours) exclusively. Patients were evaluated for DVT or pulmonary embolus based on clinical suspicion using computed tomographic angiography, ventilation and perfusion scan, or lower extremity doppler. RESULTS: A total of 214 patients were identified who met study criteria. Dalteparin was administered to 103 patients, and UFH was administered to 111. The rates of clinically significant DVT or pulmonary embolus in patients receiving dalteparin and UFH were 8.9% and 1.2%, respectively (P = .009). Major risk factors for DVT or pulmonary embolus, including age, obesity, duration of surgery, and type of malignancy, did not differ between groups. There were no significant differences in bleeding complications or transfusion requirements between groups. CONCLUSION: The low-molecular-weight heparin dalteparin dosed 5,000 U daily is inadequate postoperative prophylaxis in women undergoing surgery for gynecologic cancer. In addition, heparin administered every 8 hours was not associated with increased bleeding complications. The use of dalteparin at the doses used in this study should be questioned until a large randomized trial shows efficacy m these high-risk patients. (c) 2005 by The American College of Obstetricians and Gynecologists.
引用
收藏
页码:1006 / 1011
页数:6
相关论文
共 50 条
  • [41] Low-molecular-weight heparin in oncology
    Zacharski, LR
    Loynes, JT
    ANTICANCER RESEARCH, 2003, 23 (3C) : 2789 - 2793
  • [42] DANAPAROID IS NOT A LOW-MOLECULAR-WEIGHT HEPARIN
    SPINLER, SA
    CZIRAKY, MJ
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1994, 51 (16): : 2050 - 2050
  • [43] Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions
    Serra, A
    Esteve, J
    Reverter, JC
    Lozano, M
    Escolar, G
    Ordinas, A
    THROMBOSIS RESEARCH, 1997, 87 (04) : 405 - 410
  • [44] Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) following major abdominal surgery for malignancy.
    Rasmussen, MS
    Wille-Jorgensen, P
    Jorgensen, LN
    Nielsen, JD
    Horn, A
    Mohn, AC
    Somoed, L
    Olesen, B
    Harvald, T
    Pilsgaard, B
    Neergaard, K
    Hansen, H
    BLOOD, 2003, 102 (11) : 56A - 56A
  • [45] The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study
    Wallentin, L
    Dellborg, M
    Lindahl, B
    Nilsson, T
    Pehrsson, K
    Swahn, E
    CLINICAL CARDIOLOGY, 2001, 24 (03) : I12 - I14
  • [46] Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study
    Yasuji Inamo
    Katsuya Saito
    Maki Hasegawa
    Rika Hayashi
    Takahiro Nakamura
    Osamu Abe
    Teruaki Ishikawa
    Yayoi Yoshino
    Koji Hashimoto
    Tatsuo Fuchigami
    BMC Pediatrics, 14
  • [47] PHARMACOKINETICS OF UNFRACTIONATED HEPARIN AND OF LOW-MOLECULAR-WEIGHT HEPARIN
    BONEU, B
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 872 - 872
  • [48] Unfractionated heparin or low-molecular-weight heparin in the elderly
    Dorobantu, Maria
    Bogdan, Stefan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 222 : 1084 - 1090
  • [49] Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin®) in atrial fibrillation and TEE-guided cardioversion
    Bechtold, H
    Gunzenhauser, D
    Sawitzki, H
    Fung, S
    Janssen, D
    ZEITSCHRIFT FUR KARDIOLOGIE, 2003, 92 (07): : 532 - 539
  • [50] Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury
    Malm, K
    Dahlbäck, B
    Arnljots, B
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2003, 111 (05) : 1659 - 1666